cardiovascular benefits of glp 1 agonists The GLP-1 Therapy: Beyond Weight Loss Cardiovascular benefits of glucagon-like peptide-1
Description
Qsymia has no direct glucose-lowering mechanism
Lazzini S, Polinelli W, Riva A, et al
The 2025 review also reported that in a large retrospective study of 461,328 adults initiating GLP-1 therapy, over 22% developed at least one nutritional deficiency within 12 months, with vitamin D the most common deficiency identified
Weekly injections remain foundational, but daily oral therapy adds another entry point into care, particularly for patients hesitant about needles or seeking a treatment that fits more seamlessly into a morning routine
Potential competing interests: A.M.E.: None
